drugset / Trial / NCT05744440
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic natural killer(NK) cells in subjects with refractory or relapsed AML after allogeneic hematopoietic stem cell transplantation(allo-HSCT). A leukapheresis procedure will be performed to manufacture NK cells. Prior to allogenic NK cells infusion subjects will receive chemotherapy with azacitidine.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2025-05
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogenic NK cells | Cell therapy | 1e+07 cells/kg | Other |
| Subject | Allogenic NK cells | Cell therapy | 5e+07 cells/kg | Other |